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Summary 
 
Elective pelvic lymph node (PLN) radiotherapy and hypofractionation for advanced localised prostate 
cancer remains controversial. We report a single-centre sequential cohort study using IMRT to 
deliver conventionally-fractionated 50Gy, 55Gy, and 60Gy to the PLN and 70-74Gy (2Gy/fraction) to 
the prostate. Additionally we studied modest hypofractionation delivering 60Gy (3Gy/fraction) to 
the prostate with 47Gy to the PLN over 4-5 weeks. Our findings highlight the safety of dose-
escalation and hypofractionation in PLN-IMRT. 
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Title: A phase I/II dose escalation study of the use of intensity modulated radiotherapy 
(IMRT) to treat the prostate and pelvic nodes in patients with prostate cancer 
 
Abstract: 
Background 
The role of pelvic lymph node (PLN) radiotherapy in advanced localised prostate cancer (PCa) remains 
controversial. In order to minimise toxicity, past studies limited the dose delivered to the PLN.  We used 
Intensity Modulated Radiotherapy (IMRT) to investigate the feasibility of dose-escalation and 
hypofractionation of PLN-IMRT in PCa. 
Methods 
In a phase I/II study, patients with advanced localised PCa were sequentially treated with 70-74Gy to the 
prostate and dose-escalating PLN-IMRT at doses of 50Gy (Cohort 1), 55Gy (Cohort  2) and 60Gy (Cohort 3) in 
35-37 fractions.  Two hypofractionated cohorts received 60Gy to the prostate and 47Gy to PLN in 20 fractions 
over 4 weeks (Cohort 4) and 5 weeks (Cohort 5).  All patients received long-course androgen deprivation 
therapy.  Primary outcome was late RTOG toxicity at 2 years post-radiotherapy for all cohorts.  Secondary 
outcomes were acute and late toxicity using other clinician/patient-reported instruments and treatment 
efficacy. 
Findings 
Between Aug 9, 2000 and June 9, 2010, 447 patients were enrolled. Median follow-up was 90 months. The 2-
year rates of grade 2+ bowel/bladder toxicity were: Cohort 1 - 8.3%/4.2% (95%CI 2.2-29.4/0.6-26.1); Cohort 2 - 
8.9%/5.9% (4.1-18.7/2.3-15.0); Cohort 3 - 13.2%/2.9% (8.6-20.2/1.1-7.7); Cohort 4 - 16.4%/4.8% (9.2-28.4/1.6-
14.3); Cohort 5 - 12.2%/7.3% (7.6-19.5/3.9-13.6).  Prevalence of bowel and bladder toxicity appeared stable 
over time. Other scales mirrored these results. The biochemical/clinical failure-free rate was 71% (66-75%) at 5 
years for the whole group with pelvic lymph node control in 94% of patients. 
Interpretation 
The study shows the safety and tolerability of PLN-IMRT. Ongoing and planned phase III studies will need to 
demonstrate an increase in efficacy using PLN-IMRT to offset the small increase in bowel side-effects 
compared with prostate-only IMRT. 
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1 – Introduction 
Prostate cancer is the most common cancer in men, accounting for 27% of new cancer cases in 2014 and more 
than 307,000 men died from prostate cancer in 2012 worldwide.
1,2
 In the UK 46,690 new cases were diagnosed 
in 2014.
2
 Most men are now diagnosed with localised disease but high-risk prostate cancer remains life-
threatening. Treatment with external-beam radiotherapy (EBRT), androgen-deprivation therapy (ADT) and, in 
selected cases, high-dose rate brachytherapy have been used in this patient group.
3
 About 15,800 men receive 
radical prostate radiotherapy every year in the UK.
4
 However, the merit of elective pelvic lymph node 
radiotherapy (PLNRT) compared with treatment of prostate and seminal vesicles alone remains controversial 
and present guidelines suggest that PLNRT should be considered but not mandated for high-risk disease.
1,5
 This 
uncertainty may relate to the modest doses of radiotherapy which are usually given with PLNRT so as to avoid 
bowel toxicity. 
Intensity-modulated radiotherapy (IMRT) makes it possible to increase bowel sparing, which is the dose-
limiting normal tissue when treating the pelvis.6,7 IMRT brings the opportunity to dose escalate which has been 
linked with increased disease control in prostate cancer.
8–11
 The low α/β ratio of prostate cancer makes 
hypofractionation an attractive option for treatment, with recent data demonstrating equivalent outcomes to 
standard dose schedules treating the prostate alone.
4
 Dose escalation and hypofractionation have not been 
adequately evaluated for pelvic LNRT, with limited data available from small case series.8–10,12 
The aim of this study was to test the feasibility of using IMRT to deliver LNRT to patients with high risk prostate 
cancer, using dose escalated conventional and hypofractionated schedules. 
 
 2 – Methods 
2.a - Study design and participants 
We performed a single-centre phase I/II study of IMRT to irradiate the prostate and pelvic lymph nodes (PLN) 
in patients with advanced localized prostate cancer. Eligible patients had prostate cancer with very high risk 
(T3b/T4) or node positive disease, high risk disease with Gleason score ≥8 or ≥ 2 risk factors, or an estimated 
risk of nodal metastases of >30% based on the Roach formula.
1,13
 Post-prostatectomy patients (T2-T3a, N0) 
with extensive Gleason score ≥8 disease, seminal vesicle or lymph node involvement were also eligible.  
Patients unsuitable for radical radiotherapy, or with a history of pelvic surgery, or inflammatory bowel disease 
were excluded. 
Patients were sequentially assigned to receive three different dose-schedules to the PLN of 50, 55, or 60Gy 
(cohorts 1, 2, 3 respectively) giving 70-74Gy in 2Gy fractions over 7 weeks to the prostate. An integrated boost 
of 5Gy was given to radiologically suspicious PLN. Two hypofractionated cohorts (cohorts 4 and 5) were then 
studied, based on equivalent doses to the conventional schedule calculated assuming an α/β ratio of 2·5Gy. 
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They received 60Gy to the prostate in 3Gy fractions over 4-5 weeks and 47Gy to the PLN. An integrated boost 
of 4Gy was given to radiologically suspicious PLN. Patients were initially treated in a 4-week schedule (cohort 
4), which was later modified to a 5-week schedule (cohort 5) because of acute GI toxicity. Patients irradiated 
post-prostatectomy received 64Gy in 32 fractions in cohorts 1 and 2, 65Gy in 35 fractions in cohort 3, or 55Gy 
in 20 fractions in cohorts 4 and 5 (Appendix table SUPP-1).  
2.b - Procedures 
Patients received long course (2-3years) androgen deprivation therapy (ADT) with at least 6 months treatment 
before radiotherapy commenced.   
Patients underwent planning CT-scans with a comfortably full bladder and empty rectum. From 2011, sodium 
citrate enemas were used for patients with rectal dilatation. Inverse radiotherapy planning was performed for 
all patients using mandatory normal tissue dose-constraints (Appendix table SUPP-2) as previously 
described.
14,15
 CTV1 included the prostate and any radiologically involved seminal vesicle, with a margin of 
8mm posteriorly and 10mm in all other directions to create PTV1.  CTV2 included PLN and uninvolved seminal 
vesicles (Appendix 2).  A uniform margin of 5mm was applied to create PTV2. CTV3 included any radiologically 
involved lymph nodes and uniform margin of 5mm was applied to create PTV3. All organs-at-risk were 
contoured as solid organs, by defining the outer wall of rectum, bowel and bladder.  The rectum was 
contoured from the anus (usually at the level of the ischial tuberosities or 1cm below the lower margin of the 
PTV whichever was more inferior) to the recto-sigmoid junction.  Bowel was outlined separately, excluding 
rectum and extending 2cm above the superior extent of PTV2. Bladder was outlined from base to dome. 
Treatment verification was performed  offline using bony anatomy for registration (Appendix text SUPP-1). 
Staging investigations included PSA, histological diagnosis, radiological or surgical lymph node assessment and 
staging MRI, CT, or bone scan.  
Acute side-effects were recorded weekly using the RTOG scoring system up to 18 weeks after initiating 
radiotherapy. Late toxicity was scored according to the EORTC/RTOG and LENT/SOM late toxicity scales, and 
UCLA-PCI patient-reported outcomes.
16–18
 Data was collected at baseline, 6-monthly up to five years post 
radiotherapy and yearly thereafter. 
PSA was measured 6-monthly for 8 years after the start of ADT and annually thereafter.  The nadir PSA was the 
lowest level recorded post radiotherapy. Biochemical failure was defined according to the Phoenix consensus 
guidelines as a PSA value greater than the nadir plus 2ng/ml.  Local recurrence was confirmed on MRI pelvis or 
biopsy and post-prostatectomy patients (n=34) were excluded from this endpoint.  Distant relapse was 
confirmed on MRI, CT scan, bone scan, or choline PET-CT scan.   
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 2.c – Statistical considerations 
The primary endpoint was late RTOG toxicity assessed 2 years after radiotherapy. Secondary endpoints 
included assessment of all toxicity scales during follow-up and disease recurrence. Patients were stratified by 
total bowel volume outlined (<450cc vs. ≥450cc). For each dose level stratified by bowel volume, at least 15 
men were treated and followed up for at least 1 year. If 0 of 15 men had a grade ≥3 RTOG complication, then a 
≥20% grade ≥3 toxicity rate was excluded with one sided significance level 0.05. As the dose to the initial 
cohort was modest, patients in the low bowel volume group were recruited to the second dose level after 
seven men had ≥12 months of follow-up, provided none of these had recorded a grade 3 or higher 
complication. For other cohorts and bowel volume groups, recruitment continued at that level until such time 
as fifteen men had been treated and followed up for at least one year. This strategy ensured that the low 
bowel volume group moved to the higher dose cohorts in advance of the high bowel volume group. Because 
recruitment continued in each cohort and bowel volume group until such time as the required total of men 
had reached ≥12 months of follow-up, in all cases the eventual sample size in each group exceeded the 
required total to an extent which varied according to the recruitment rate over time.  
In cohorts 3 and 4, a further dose expansion phase was planned, with a target sample size of 103 patients (of 
any bowel volume) evaluable at 2 years in order to rule out a late grade 2 or over (grade 2+) bowel toxicity 
rate of >=25%, using a one-sided alpha 0·05 and power of 80% with an assumed true rate of toxicity not more 
than 15%. The sample size was expanded to a total of 123 in each of cohort 3 and 4 to allow for an expected 
drop-out rate of 16% by 2 years. However, due to high levels of acute bowel toxicity observed in cohort 4 (4-
weekly schedule), the treatment schedule was amended to 5 weeks (cohort 5) with a target of 123 patients. 
Late toxicity rates were calculated using Kaplan-Meier methods with time measured from start of 
radiotherapy. Rates by 1 and 2 years were calculated with 95% confidence intervals (CI).  One-sided 95% CI 
were constructed for rate of RTOG grade 3+ bowel toxicity at 1 year (cohort 1 and 2) and for rate of RTOG 
grade 2+ bowel toxicity at 2 years (cohorts 3 and 4) in order to assess safety of the primary endpoint. In 
addition, the number of men experiencing defined toxicity grades at each timepoint was reported as a 
percentage of all men assessed. Efficacy was assessed using Kaplan-Meier methods to calculate length of 
disease control (defined as a composite endpoint of biochemical progression, local or lymph node/pelvic 
recurrence, or distant metastasis, or recommencement of androgen deprivation therapy), length of local 
disease control, length of distant disease control, disease specific, and overall survival from start of 
radiotherapy.  For disease specific and overall survival, patients were censored at the date they were last 
known to be alive.  Rates at 2 and 5 years were calculated with 95% CI. Data was extracted in September 2015 
and analysed using STATA v13.1. 
Univariable Cox regression on length of disease control was performed using factors of dose cohort, N-stage 
(N0 vs. N1-3), baseline PSA (log transformed), clinical T-stage (grouped as T1/T2; T3a; T3b+) and Gleason score 
(grouped as ≤6; 7; ≥8). Forward and backward stepwise selection methods were used to combine significant 
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factors (p<0·05 on univariable analysis) into a multivariable model and produce adjusted hazard ratios with 
95% CI. 
2.d – Trial setup 
Institutional clinical research and ethics committees approved the study which was included in the National 
Cancer Research Network (NCRN) portfolio in December 2003. The trial was performed in accordance with the 
principles of good clinical practice and overseen by a trial management group. All patients provided written 
informed consent.  
 
3 –Outcomes 
Between Aug 9, 2000 and  June 9, 2010, 447 male patients were recruited to cohorts 1-5, 426 were treated 
according to protocol and 421 were available for late toxicity assessment (Figure 1). Median age was 65 years 
(IQR: 60-70yrs) with median presenting PSA of 21·4ng/ml (10·2-42·8). 46% of patients had clinical T3/T4 
disease, 54% had Gleason 8 or over scores, and 17% PLN involvement. Cohort 1 had a higher proportion of 
patients with adverse features than cohorts 2-5. Median duration  of adjuvant hormone therapy was 35 
months (33-37 months)  and median follow-up was 90 months (Table 1), with 398 patients out of 426 
followed-up for toxicity for at least 2 years and 327 followed up for at least 5 years. Thirty-four patients (8%) 
were treated adjuvantly after undergoing a radical prostatectomy prior to entering the trial (table SUPP-6). 
Acute bowel toxicity peaked at 6-8 weeks in the conventionally-fractionated (CFRT) cohorts 1-3, compared 
with 4-5 and 5-6 weeks in the hypofractionated (HFRT) cohorts 4-5 respectively. Peak grade 2+ toxicity was 
recorded in 40%, 56%, and 54% of cohorts 1-3 respectively. Patients in cohort 4 developed the highest acute 
bowel toxicity rates, with 66% reporting grade 2+ bowel toxicity compared with 48% in cohort 5. However, by 
18 weeks post-treatment the incidence of grade 2+ RTOG bowel toxicity was similar in all cohorts (Figure 2 and 
Appendix table SUPP-3). Acute grade 3+ peak toxicity occurred in 0 (0%), 1 (1%), 5 (4%), 3 (5%), and 9 (7%) 
patients in cohorts 1-5 respectively. One patient in each of cohorts 4 and 5 developed grade 4 acute toxicity 
and there was one death (recorded as Grade 5 toxicity), determined at autopsy to have resulted from 
perforation of an undiagnosed caecal carcinoma. 
Acute bladder toxicity was related to dose in the CFRT cohorts, with peak  grade 2+ toxicity recorded in 28%, 
44%, and 53% patients in cohorts 1-3 respectively. Patients in cohort 4 experienced higher rates of bladder 
toxicity of grade 2+ (61%) than patients in cohort 5 (53%). However, rates of grade 2+ bladder toxicity at 18 
weeks were low and similar in all cohorts (Figure 2). 
The 2-year cumulative rate of RTOG grade 2+/grade 3+ bowel toxicity was 8·3% (95% CI 2·7-24·3)/0%, 8·9% 
(4·1-18·7)/1·5% (0·2-10.4), and 13·2% (8·6-20·2)/2·2% (0·7-6·7) in cohorts 1-3 (CFRT) respectively. In the HFRT 
cohorts 4-5, the 2 year rate of grade 2+/grade 3+ bowel toxicity was 16·4% (9·2-28·4)/6·6% (2·5-16·7), and 
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12·2% (7·6-19·5)/0·8% (0·1%-5·7%) respectively (Figure 3 and Appendix tables SUPP-4 and SUPP-5). A 
comparable 12·2% (4·7-29·3) of post-prostatectomy patients experienced grade 2+ bowel toxicity, with no 
clear difference between the cohorts in view of the small numbers included (table SUPP-6). 
The 2-year cumulative rates of grade 2+/grade 3+ bladder toxicity were 4·2% (0·6-26·1)/4·2% (0·6-26·1), 5·9% 
(2·3- 15·0)/2·9% (0·7-11·3), and 2·9% (1·1-7·7)/ 2·2% (0·7-6·8) in cohorts 1-3 (CFRT) respectively. In cohorts 4-5 
(HFRT), rates were 4·8% (1·6-14·3)/1·6% (0·2-10·9), and 7·3% (3·9-13·6)/1·2% (0·4-6·4) respectively (Figure 3 
and Appendix tables SUPP-4, SUPP-5 and SUPP-6). Post-prostatectomy patients had a higher rate of urinary 
symptoms at 9·0%, albeit with a large CI (3·0-25·4), with no clear differences between cohorts (table SUPP-6). 
The prevalence of bowel and bladder toxicity appeared stable over time (Figure 3 and Appendix tables SUPP-4 
and SUPP-5). At 5 years follow-up, 0/0 (0%/0%), 1/0 (2%/0%), 5/1 (5%/1%), 3/0 (6%/0%), and 2/0 (2%/0%) 
men had grade 2+/3+ RTOG bowel toxicity in cohorts 1-5 respectively. The 5-year prevalence of grade 2+ 
bladder toxicity was 0/0 (0%/0%), 2/0 (4%/0%), 1/0 (1%/0%), 2/2 (4%/4%), and 3/1 (3%/1%) in cohorts 1-5 
respectively. 
All estimates of late toxicity met predefined safety criteria. Results using the RMH and LENT/SOM assessments 
are given in Appendix tables SUPP-4 and SUPP-5. Table SUPP-6 details rates of late symptoms in patients 
treated post-prostatectomy. 
Patient-reported outcomes (PRO) were obtained with the UCLA-PCI instrument (Appendix tables SUPP-4 and 
SUPP-5). The cumulative 5-year rate of small or worse bowel/bladder bother was 26% (95% CI 13-50)/ 37% 
(19-63), 49%(37-63)/ 35%(24-49), 38% (30-48)/ 35% (27-45), 56% (43-69)/ 45% (32-59), and 54% (44-64)/ 46% 
37-57) in cohorts 1-5 respectively. Prevalence of moderate/severe bowel problems at 2 years was 1/22 (5%), 
4/47 (9%), 6/84 (7%) , 4/45 (9%), and 10/85 (12%) in cohorts 1-5 respectively. Moderate/severe urinary 
problems at 2 years were reported by 1/22 (5%), 5/47 (10%), 6/85 (7%), 6/47 (13%), and 10/85 (12%) in 
cohorts 1-5 respectively. At 5 years, prevalence rates for moderate/severe bowel problems were 0/12 (0%), 
1/42 (2%), 1/76 (1%), 2/35 (6%), and 2/54 (4%) in cohorts 1-5 respectively. No severe bowel problems were 
reported at 5 years. Prevalence of moderate/severe urinary problems at 5 years was 0/12 (0%), 2/42 (4%), 
6/78 (7%), 2/35 (6%), and 3/57 (5%) in cohorts 1-5 respectively. No men in the HFRT cohorts had severe 
urinary problems at 5 years.  
Biochemical or clinical progression occurred in 169/426,(39·7%) of patients. At first-relapse, biochemical 
failure alone occurred in 141/169 (59%), local recurrence in 11/169 (7%), distant metastases in 7/169 (4%), 
and 3/169 (2%) patients commenced salvage hormone therapy in the absence of radiological confirmation of 
sites of disease. On subsequent follow-up there were 41/426 (10%) confirmed relapses within the prostate, 
26/426 (6%) PLN recurrences, 39/426 (9%) relapses in distant nodal groups, and 99/426 (23%) relapses at 
other metastatic sites. The biochemical/clinical failure-free rate was 71% (95% CI 66-75%) at 5 years for the 
whole group, with 38%, 61%, 70%, 80%, and  78% remaining recurrence free in cohorts 1-5 respectively.  
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Disease specific survival at 5 years was 92% (95% CI 89-94%) for the whole cohort and 79%, 88%, 92%, 97%, 
and 95% in cohorts 1-5 respectively .  The 5-year overall survival was 87% (95%CI 84-90%) and 76%, 87%, 86%, 
89%, and 91% in cohorts 1-5 respectively (Figure 4). 
Multivariate analysis identified pre-treatment PSA level (p=0·004), PLN involvement (p=0·02), T stage (p=0·05), 
and dose cohort (p=0·05) as factors associated with length of disease control. Patients treated in cohorts 4 and 
5 had similar outcomes (Table 2). 
 
4 – Discussion 
We found acceptable acute and late GI/GU toxicity measured using both CRO and PRO in all patient cohorts. 
To assess the impact of PLNRT, we compared these results with a large contemporaneous group of patients 
treated in the CHHiP phase III trial, which used IMRT to treat the prostate alone using similar CFRT/HFRT 
schedules and scored side-effects with the same compendium of CRO and PRO.
4
 We also used comparable 
data reported in a recent systematic review (Holch et al.), which included no studies with PLNRT.
19
 We found 
that acute grade 2+ GI toxicity occurred in 40-56% of CFRT patients in cohorts 1-3 compared to 25% in CHHiP 
and 21-60% in Holch et al., with a rate of 66% in cohort 4 (four-week HFRT) compared to 30% in the CHHiP 
HFRT group and 36% in Holch et al. Increasing the overall treatment-time to five weeks reduced the rate to 
48% in cohort 5.  However, these side-effects settled rapidly in all groups. There were no differences in grade 
2+ toxicity by 18 weeks, although some increase in mild grade 1+ side effect rates persisted with PLNRT (25-
36% compared with 21% in CHHiP).  There were no clear differences between grade 2+ peak/week 18 or grade 
1+ week 18 GU toxicities between cohorts 1-5 or when comparing with the CHHiP or Holch et al. GU toxicity 
rates (Appendix table SUPP-3). 
Late GI side-effects appeared highest in cohort 4 using clinician-reported outcomes (CRO) scales, both two and 
five years after treatment.  For example, two-year estimated cumulative proportions with grade 2+ (CRO) or 
small or worse bowel problems (PRO) were 16%, 16%, 34%, and 53% using the RTOG, RMH, LENT-SOM and 
UCLA-PCI scales, respectively, compared with 8-13%, 8-15%, 13-25%, and 21-43% for the other cohorts.  The 
rates for the comparator CHHiP group were 8-9%, 10-11%, 16-18%, and 25-27% respectively. Applicable results 
in the Holch et al. systematic review were similar to CHHiP. The increased acute and late GI toxicity seen in 
Cohort 4 would be consistent with a consequential late side-effect.
20,21
  Extending treatment duration to five 
weeks by treating four times per week appears to reduce any impact of hypofractionation (Appendix tables 
SUPP-4 and SUPP-5). 
Late GU side-effects, assessed using RTOG and RMH CRO scales, were similar between all groups with no 
obvious impact from dose, fractionation schedule or use of PLNRT.  However, the cumulative proportion of 
patients with grade 2+ toxicity (LENT-SOM, CRO) or small or worse bladder bother (UCLA-PCI, PRO) at 2 years 
was somewhat higher than in the CHHiP groups, suggesting these scales are more sensitive.  Any differences 
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had disappeared by five years, when the prevalence of small or worse bladder bother was 8-20% in cohorts 1-5 
and 17% in the CHHiP comparator group (Appendix tables SUPP-4 and SUPP-5). 
Late bowel and bladder side-effects did not show consistent differences when the sub-group of patients 
treated post-prostatectomy were analysed, either with CRO or PRO data (table supp-6). However, these results 
should be interpreted with caution given that only 34 patients were treated adjuvantly in this trial and limited 
conclusions can be drawn. 
The low level of side-effects seen in the present series probably relates to the use of a strict IMRT protocol and 
the mandating of dose-constraints for both bowel and bladder. However the doses delivered in cohorts 3-5 are 
at least 10% higher than used in past and contemporary practice (Appendix figure 1). Similar dose increments 
have been shown to improve disease outcome in trials treating the prostate alone.
22,23
 
The 5-year OS in this series (87%; 95% CI 84-90%) is at least comparable to a recent retrospective series from 
the National Cancer Database in which 7606 patients were treated with PLNRT with 5-year overall survival of 
81.6%.
24
  In the group randomised to PLNRT in the RTOG 94-13 trial, a 4-year OS of 84% was reported. The 5-
year biochemical/clinical failure free rate of 71% for our entire series is similar to the control group treated 
with radiotherapy in the contemporaneous MRC STAMPEDE trial which showed an estimated 75%/50%  5-year 
control in patients with N0/N1 disease respectively.
25
 
The low pelvic lymph node recurrence rate of 6% is reassuring, but further efforts to improve local control in 
the prostate for patients with aggressive bulky disease appear warranted (hazard ratio for local disease control 
in T3b+: 1·70, 95% CI 1·11-2·60; Table 2). Approaches using high dose focal radiotherapy boosts, 
prostatectomy or additional ablative focal therapies using, for example, high intensity focussed ultrasound or 
cryotherapy can be considered.
26
  Avoidance of toxicity, however, is important, as a considerable majority of 
patients have disease controlled by IMRT and androgen-deprivation therapy or, alternatively, relapse with 
metastatic disease outside the pelvis, making additional measures to improve local control futile.  The 
development of biomarkers to predict the response to radiotherapy and define patient groups destined to 
develop metastatic disease would therefore be invaluable in guiding treatment individualisation.
27
 Treatment 
intensification with additional systemic treatments, such as docetaxel or the new generation of hormonal 
therapies, can be considered.
28
 Additionally, radiogenomic and dosimetric studies are aiming to refine 
estimates of an individual’s risk of developing side-effects.
29,30
 
 
5 – Conclusion 
This study has provided the safety data to encourage further investigation of high dose LNRT. The treatment 
techniques described have been generalised in a UK national phase II randomised pilot study, PIVOTAL 
(ISRCTN48709247) which compares prostate and pelvis with prostate alone IMRT.  Hypofractionated RT will 
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become the UK standard of care following the CHHiP trial.
4
 The safety data of hypofractionated schedules in 
the present study are encouraging and the use of HFRT in a new trial, PIVOTALboost, is planned. It will assess 
the value of pelvic IMRT as well as the effects of a focal high-dose intraprostatic boosts to dominant lesions. 
These studies will complement other ongoing phase III studies, RTOG 09-24 (NCT01368588) and PEACE 2 
(NCT01952223), which should finally determine the role of PLNRT in prostate cancer.  An increase in efficacy 
will need to be demonstrated to offset the small but expected adverse effects of pelvic IMRT.   
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6 – Figure legends 
Figure 1 
Title: Trial profile 
Legend: RT = radiotherapy. LN = lymph node. CFRT = Conventionally-fractionated radiotherapy. HFRT = 
Hypofractionated radiotherapy. 
 
Figure 2 
Title: Acute RTOG grade 2+ toxicity by timepoint and treatment group. 
Legend: A: Prevalence of acute RTOG grade 2+ bowel toxicity (A) and of acute RTOG grade 2+ bladder toxicity 
(B). RTOG = Radiation Therapy Oncology Group scale. Grade 2+=score of grade 2 or worse. 
 
Figure 3 
Title: Late bowel and bladder toxicity by timepoint, assessment, and treatment group. 
Legend: Grade distribution of (A) bowel adverse events and (B) bladder adverse events measured with RTOG. 
Cumulative incidence of (C) grade 2+ bowel adverse events measured with RTOG and (E) small or worse bowel 
symptom scores measured with UCLA-PCI. Cumulative incidence of (D) grade 2+ bladder adverse events 
measured with RTOG and (F) small or worse bladder symptom scores measured with UCLA-PCI. 
RTOG=Radiation Therapy Oncology Group scale. UCLA-PCI=UCLA Prostate Cancer Index. Grade 2+=grade 2 or 
worse adverse event. 
 
Figure 4 
Title: Biochemical failure-free survival (A), disease-specific survival (B) and overall survival (C). 
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Table 1 
 
Title: Patient Demographics. 
Legend: Data are n (%) or median (IQR) unless otherwise stated. NCCN=National Comprehensive Cancer Network. PSA = 
prostate-specific antigen. ADT = androgen deprivation therapy. CT = Computed Tomography. MR = magnetic resonance. 
 
Cohort 1  
50Gy  
(n=25) 
Cohort 2  
55Gy  
(n=70) 
Cohort 3  
60Gy  
(n=138) 
Cohort 4 
47Gy/4wks 
(n=64) 
Cohort 5 
47Gy/5wks 
(n=129) 
Cohorts 1-5  
n=426 
Age at Diagnosis 
(years) 
63 (56-67) 62 (57-67) 65 (59-69) 66 (62-72) 67 (62-71) 65 (60-70) 
PSA at Diagnosis 
(ng/mL) 
39.1  
(24.7-78.0) 
25.4 
(12.4-44.7) 
24.5 
(10.2-47.1) 
15.4 
(8.5-31.4) 
18 
(8.1-37.9) 
21.4 
(10.2 – 42.8) 
Gleason Score 
Gleason ≤7 13 (52%) 34 (48%) 60 (43%) 22 (35%) 56 (44%) 185 (44%) 
Gleason 8 4 (16%) 17 (24%) 29 (21%) 13 (20%) 11 (9%) 74 (17%) 
Gleason ≥9 6 (24%) 16 (22%) 48 (35%) 28 (44%) 60 (47%) 158 (37%) 
Unknown 2 (8%) 3 (4%) 1 (1%) 1 (2%) 2 (2%) 9 (2%) 
CT/MR N Stage 
N0 16 (64%) 49 (70%) 115 (83%) 51 (80%) 110 (85%) 341 (80%) 
N1 9 (36%) 14 (20%) 22 (16%) 11 (17%) 18 (14%) 74 (17%) 
Unknown 0 (0%) 7 (10%) 1 (1%) 2 (3%) 1 (1%) 11 (3%) 
Clinical T Stage 
cT1/T2 18 (32%) 23 (33%) 60 (43%) 6 (9%) 42 (32%) 156 (37%) 
cT3 17 (68%) 34 (49%) 57 (41%) 17 (27%) 56 (43%) 192 (45%) 
cT4 0 (0%) 2 (3%) 3 (2%) 28 (44%) 1 (1%) 6 (1%) 
Unknown 0 (0%) 11 (16%) 18 (13%) 13 (20%) 30 (23%) 72 (17%) 
Duration of ADT 
(months)  
36 
(32-36) 
35 
(33-37) 
36 
(33-40) 
34 
(33-36) 
35 
(34-37) 
35 
(33-37) 
Median length of 
follow-up (years) 
13.9 11.2 9.0 7.1 5.7 7.6 
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Title: Multivariate cox regression analysis, for length of disease control (n=326). 
Legend: Hyp.=Hypofractionated. 
 
Factor Levels Hazard Ratio  (95% CI) p-value 
Dose Cohort 
Cohort 1 - 50Gy 
Cohort 2 - 55Gy 
Cohort 3 - 60Gy 
Cohort 4 - Hyp. 4 wk 
Cohort 5 - Hyp. 5 wk 
1 (NA) 
0.71 (0.40, 1.26) 
0.45 (0.26, 0.80) 
0.50 (0.25, 1.01) 
0.45 (0.24, 0.84) 
0.05 
 
Log max  
pre-treatment PSA Continuous. ng/ml 1.30 (1.08, 1.57) <0.01 
Clinical T-stage 
T1/T2 
T3a 
T3b+ 
1 (NA) 
1.22 (0.78, 1.91) 
1.70 (1.11, 2.60) 
0.05 
Radiological N stage N0 N+ 
1 (NA) 
1.65 (1.09, 2.48) 0.02 
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